文献速递肝病

体内碱基编辑改善HFE相关遗传性血色病铁蓄积与纤维化

In vivo base editing alleviates hepatic iron accumulation and fibrosis in models of HFE-related hereditary hemochromatosis.
PubMed 文献 · J Hepatol · 2026-06-10

该研究采用脂质纳米颗粒递送碱基编辑器mRNA和sgRNA,在小鼠模型及患者iPSC来源肝细胞样细胞中纠正HFE C282Y突变。小鼠体内校正效率达67%,患者细胞达63.8±0.8%,均未检测到脱靶效应;治疗小鼠肝铁过载显著减轻,纤维化和癌症相关转录特征下降。

要点

  • LNP递送碱基编辑可高效纠正HFE C282Y,小鼠体内效率达67%。
  • 治疗小鼠肝铁蓄积显著减少,纤维化和癌症相关转录特征下降。
  • 患者iPSC来源肝细胞样细胞校正效率达63.8±0.8%,未检测到脱靶。

核心结论

  • 碱基编辑纠正HFE C282Y在体内和人体来源细胞中安全高效,可减少肝铁蓄积并阻止纤维化重塑。

研究设计与样本

  • 研究采用LNP递送碱基编辑器mRNA和sgRNA,在铁负荷小鼠模型中体内纠正HFE C282Y突变。
  • 同时使用患者来源iPSC分化的肝细胞样细胞,以相同方法进行编辑。

主要发现

  • 培养小鼠肝细胞转换率为73.6±4.9%,体内高达67%。
  • 在有一或两个错配的基因组位点未检测到脱靶效应,经下一代测序确认。
  • 治疗小鼠尽管持续高膳食铁摄入,肝铁过载仍显著减少。
  • 转录组分析显示纤维化和癌症相关特征减少。
  • 患者iPSC来源肝细胞样细胞经LNP介导碱基编辑,校正率达63.8±0.8%,未检测到脱靶活性。

关键数值与推荐

  • HFE C282Y纯合子占诊断病例的80-90%。

临床怎么用

  • 该结果为HFE C282Y相关血色病的非病毒基因纠正提供了转化潜力,但需更大规模和长期研究验证。

局限性

  • 需在更大规模和长期研究中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: HFE-related hereditary hemochromatosis is caused by loss-of-function mutations in the HFE gene, leading to excessive intestinal iron absorption and hepatic deposition. The C282Y variant in homozygosity accounts for 80-90% of diagnosed cases. If untreated, iron accumulation can cause liver fibrosis, cirrhosis, and hepatocellular carcinoma. METHODS: We employed lipid nanoparticles (LNPs) to deliver base editor mRNA and single-guide RNA for in vivo correction of the HFE C282Y mutation in a murine model under iron challenge. Additionally, patient-derived induced pluripotent stem cells (iPSCs) and hepatocyte-like cells were edited using the same approach. RESULTS: Base editing achieved a conversion rate of 73.6 ± 4.9% in cultured murine hepatocytes and up to 67% in vivo. No off-target effects were detected at genomic sites with one or two mismatches, as confirmed by next-generation sequencing. Treated mice showed significantly reduced hepatic iron overload despite continued high dietary iron intake. Transcriptomic analysis revealed decreased signatures associated with fibrosis and cancer. For preclinical evaluation, iPSCs from C282Y homozygous patients were differentiated into hepatocyte-like cells. LNP-mediated base editing achieved up to 63.8 ± 0.8% correction in these cells, again without detectable off-target activity. CONCLUSIONS: These results provide proof of concept that base editing of the C282Y variant is both safe and efficient in vivo and in human-derived cells, effectively reducing hepatic iron accumulation and preventing fibrotic remodeling. IMPACT AND IMPLICATIONS: HFE C282Y-related hemochromatosis lacks causal therapies and carries a risk of iron-driven liver disease, supporting the need for precise in vivo gene correction. Here, LNP-mediated adenine base editor delivery enabled efficient editing in hepatocytes and induced pluripotent stem cell-derived models, reducing hepatic iron and normalizing biomarkers without detectable safety concerns. These findings highlight translational potential for non-viral gene correction, though further validation in larger and long-term studies is required.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Hamann V, Hook S, Sujariyakul P, et al. In vivo base editing alleviates hepatic iron accumulation and fibrosis in models of HFE-related hereditary hemochromatosis. J Hepatol. 2026. PMID: 42269836. doi:10.1016/j.jhep.2026.05.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。